Edinburgh

KOHLER and ANN SACKS Partner with Acclaimed Designer Shea McGee on New Product Collections

Retrieved on: 
Wednesday, September 6, 2023

KOHLER, Wis., Sept. 6, 2023 /PRNewswire/ -- Kohler Co., celebrating 150 years of innovation, quality, and craftsmanship, builds on its legacy of design leadership through an exciting new collaboration with Shea McGee and her firm, Studio McGee.

Key Points: 
  • The KOHLER x Studio McGee Collection blends classic and modern design influences providing timeless expressions for the home.
  • The new luxury tiles are available through Ann Sacks Showrooms, AnnSacks.com, Kohler Signature Stores, and Kohler Experience Centers on Sept. 21.
  • "Shea's collections with KOHLER and ANN SACKS pair seamlessly for customers who aspire to explore new possibilities and create their own unique spaces throughout the home."
  • The ANN SACKS x Studio McGee Collections can be specified for wall or flooring installations.

The Front Line Foundation Will Commemorate the Sacrifices Made on September 11 with a Ceremony Prior to Golf Tournament

Retrieved on: 
Wednesday, August 23, 2023

MINNEAPOLIS, Aug. 23, 2023 /PRNewswire-PRWeb/ -- The Front Line Foundation (TFLF) announced today plans for its' annual Remembering 9.11 Golf Tournament on Monday, September 11 at Edinburgh USA Golf Club in Brooklyn Park. As part of the tournament, a ceremony will take place prior to play that honors the sacrifices of those who died on duty on that day 22 years ago.

Key Points: 
  • As part of the tournament, a ceremony will take place prior to play that honors the sacrifices of those who died on duty on that day 22 years ago.
  • "It is important that we pause and take a moment to remember the events of 9-11 and the many sacrifices our first responders make."
  • Remembering 9.11 Golf Tournament At-A-Glance:
    What: The Front Line Foundation Memorializes Minnesota's First Responders with a special ceremony commemorating 9-11-01.
  • For members of the media attending the ceremony, park in the main parking lot nearest the front door of the clubhouse.

SciSparc Announces Successful Final Phase IIa Results, Meeting End Points of its Phase IIa Alzheimer Disease Patients with Agitation Trial

Retrieved on: 
Friday, June 2, 2023

Agitation manifests over the course of AD’s progression in almost all affected patients, increasing patients’ suffering and burden of care.

Key Points: 
  • Agitation manifests over the course of AD’s progression in almost all affected patients, increasing patients’ suffering and burden of care.
  • This Phase IIa clinical trial was an open label  trial, which included 18 patients diagnosed with AD and agitation, to evaluate the safety, tolerability, and efficacy trends of twice daily oral administration of SCI-110.
  • In general, the trial medication was well tolerated with no negative response to the treatment observed throughout the trial duration.
  • Alzheimer disease' patients experience many different symptoms that deteriorate their condition including lack of appetite, sleep quality and agitation.

SciSparc Completed Treatment of Last Patient Enrolled for its Phase IIa Clinical Trial for Alzheimer's Disease and Agitation

Retrieved on: 
Tuesday, May 2, 2023

TEL AVIV, Israel, May 02, 2023 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC) (“Company” or “SciSparc”), a specialty clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders of the central nervous system, today announced that the last patient enrolled in the Company's Phase IIa trial of SCI-110 in patients with Alzheimer’s Disease (“AD”) and agitation, completed its treatment.

Key Points: 
  • TEL AVIV, Israel, May 02, 2023 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC) (“Company” or “SciSparc”), a specialty clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders of the central nervous system, today announced that the last patient enrolled in the Company's Phase IIa trial of SCI-110 in patients with Alzheimer’s Disease (“AD”) and agitation, completed its treatment.
  • The Company is expecting to receive the final trial results in the upcoming weeks.
  • On November 7, 2022, the Company announced positive interim results from the open label trial, which includes 20 patients diagnosed with AD and agitation, to evaluate the safety, tolerability and efficacy trends of twice daily oral administration of SCI-110.
  • The interim results summarize the data from the first eight patients who completed the trial as per protocol.

Edinburgh Casting Studio's World-Famous Kits now available in the USA in time for Valentine's Day

Retrieved on: 
Monday, January 23, 2023

ASPEN, Colo., Jan. 23, 2023 /PRNewswire-PRWeb/ -- The Edinburgh Casting Studio's luxury casting kits are a fun way for couples to make meaningful Valentine's Day memories that will stick in their minds forever.

Key Points: 
  • Famed for making family sculptures for the world's elite, the British company's premium hand casting kits are now available for families and couples to buy in the US.
  • ASPEN, Colo., Jan. 23, 2023 /PRNewswire-PRWeb/ -- The Edinburgh Casting Studio 's luxury casting kits are a fun way for couples to make meaningful Valentine's Day memories that will stick in their minds forever.
  • Made in the USA, but developed by the British team behind the world's most exclusive lifecasting studio, Wrightson and Platt , The Edinburgh Casting Studio's kits take home-casting to the next level.
  • Edinburgh Casting Studio Home Casting Kit Details:

The Exceptional Women Alliance (EWA) congratulates Patricia Kinane for receiving an Officer of the Order of the British Empire (OEB) in the King's New Year Honours List

Retrieved on: 
Tuesday, January 17, 2023

LOS ANGELES, Jan. 17, 2023 /PRNewswire-PRWeb/ -- Patricia "Trish" Kinane, Former President of Entertainment Programs at Fremantle Media North America, received an Officer of the Order of the British Empire (OEB) for services to Broadcasting and the International Television Format Industry in the 2023 King's New Year Honours List. Ms. Kinane was selected to the Exceptional Women Alliance (EWA) in 2020, which proudly recognizes her recent achievement.

Key Points: 
  • Ms. Kinane was selected to the Exceptional Women Alliance (EWA) in 2020, which proudly recognizes her recent achievement.
  • "Seeing one of our members get recognized for their outstanding achievements gives us reason to celebrate and acknowledge our powerful network of women," added Segil.
  • Among her many successes, in 2008 Ms. Kinane received the prestigious FRAPA International GoldFormat Award at MIPCOM in Cannes.
  • The Exceptional Women Alliance (EWA) is an invitation only peer mentorship organization where high-potential, high-level Exceptional Women from across multiple industries are hand-selected and invested in, to grow, learn, share, and succeed.

SciSparc Announced Positive Interim Results Meeting Primary Endpoints at Phase IIa Study in Alzheimer’s Disease Patients with Agitation

Retrieved on: 
Monday, November 7, 2022

Agitation manifests in the course of AD progression in almost all affected patients, increasing patients suffering and burden of care.

Key Points: 
  • Agitation manifests in the course of AD progression in almost all affected patients, increasing patients suffering and burden of care.
  • This Phase IIa clinical trial is an open label study, which includes 20 patients diagnosed with AD and agitation, to evaluate the safety, tolerability and efficacy trends of twice daily oral administration of SCI-110.
  • The interim results summarize the data from the first eight patients who completed the study as per protocol.
  • We are pleased that SCI-110 is showing clinically meaningful results and may provide a potential treatment option for Alzheimers patients with agitation, said Adi Zuloff-Shani, PhD, Chief Technology Officer of SciSparc.

Lykan Bioscience and RoslinCT Announce the Establishment of a Scientific Advisory Board

Retrieved on: 
Tuesday, September 13, 2022

and EDINBURGH, UK, Sept. 13, 2022 /PRNewswire/ -- Lykan Bioscience and RoslinCT, a leader in Contract Development and Manufacturing for cell therapies, announced the formation of its inaugural Scientific Advisory Board (SAB).

Key Points: 
  • and EDINBURGH, UK, Sept. 13, 2022 /PRNewswire/ -- Lykan Bioscience and RoslinCT, a leader in Contract Development and Manufacturing for cell therapies, announced the formation of its inaugural Scientific Advisory Board (SAB).
  • The SAB will be working closely with members of the Lykan Bioscience and RoslinCT management and scientific teams, providing valuable insight into a range of topics across the development and manufacturing of advanced therapies.
  • "The creation of a Scientific Advisory Board is a testament to our commitment to innovation on behalf of our partners," said Patrick Lucy, President & CEO of Lykan Bioscience.
  • Lykan Bioscience is an innovative contract development and manufacturing services organization (CDMO) focused on cell-based therapies.

Rachael Sage "Revelation Ground" Summer Tour: Spain Debut & UK Headline Shows

Retrieved on: 
Tuesday, June 7, 2022

NEW YORK, June 7, 2022 /PRNewswire-PRWeb/ -- Just back from a phenomenal 6-week tour of the UK & Ireland supporting Irish Folk/Rockabilly singer Imelda May, Rachael Sage will be heading to Spain to rejoin Imelda in key cities on the Iberian Peninsula. The sold-out tour of the British Isles and Ireland garnered an immense amount of accolades in the press, with the Irish Post writing she has "a wonderful way with words...very creative and emotional." Recent coverage includes articles in IMAAI, Lock Magazine, and PopMatters.

Key Points: 
  • NEW YORK, June 7, 2022 /PRNewswire-PRWeb/ -- Just back from a phenomenal 6-week tour of the UK & Ireland supporting Irish Folk/Rockabilly singer Imelda May, Rachael Sage will be heading to Spain to rejoin Imelda in key cities on the Iberian Peninsula.
  • For Sage, who has toured many other European countries but never Spain, the opportunity to bring her original folk-pop to cities such as Zaragoza and Barcelona for the first time will be a dream come true.
  • I can't wait to take it all in, and am so grateful to my brilliantly talented friend Imelda May for this unique opportunity!"
  • Sage is also a visual artist, actor and former ballet dancer who performed with the New York City Ballet.

The Galien Foundation Announces Winners of the 2022 Prix Galien UK Awards at the Natural History Museum, London

Retrieved on: 
Friday, May 13, 2022

LONDON, May 13, 2022 /PRNewswire/ -- The Galien Foundation, the premier global institution dedicated to honouring innovators in life sciences, announced winners for the 2022 Prix Galien UK Awards last night at the Natural History Museum, London. Awards for "Best Biotechnology Product," "Best Pharmaceutical Product," "Best Medical Technology" and "Best Digital Health Solution" were awarded to industry leaders dedicated to innovation that improves the human condition. In conjunction with the Prix Galien UK Awards, The Galien Foundation also announced winners for the 2022 Prix Galien International Awards for "Best Biotechnology Product," "Best Digital Health Solution," "Best Medical Technology," "Best Pharmaceutical Product" and "Best Vaccine."

Key Points: 
  • Former Chief Executive Officer of the Bill & Melinda Gates Foundation, Seattle, WA
    Professor of Internal Medicine and Therapeutics & Founder, Former President
    Honorary Distinguished Professor of Medicine, Imperial College, Committee Chair, Prix Galien UK Awards Committee
    The Galien Foundation fosters, recognises and rewards excellence in scientific innovation to improve the state of human health.
  • The Foundation oversees and directs activities in the UK for the Prix Galien, an international awards program dedicated to progress through innovative medicines development, with chapters in 14 countries and Africa.
  • The Prix Galien was created in 1970 by Roland Mehl in honour of Galien, the father of medical science and modern pharmacology.
  • Worldwide, the Prix Galien is regarded as the equivalent of the Nobel Prize in biopharmaceutical research.